U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C23H21N5O3S
Molecular Weight 447.51
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of DOMATINOSTAT

SMILES

CN1C=C(C=N1)C2=CC=C(C=C2)S(=O)(=O)N3C=CC(\C=C\C(=O)NC4=CC=CC=C4N)=C3

InChI

InChIKey=PRXXYMVLYKJITB-IZZDOVSWSA-N
InChI=1S/C23H21N5O3S/c1-27-16-19(14-25-27)18-7-9-20(10-8-18)32(30,31)28-13-12-17(15-28)6-11-23(29)26-22-5-3-2-4-21(22)24/h2-16H,24H2,1H3,(H,26,29)/b11-6+

HIDE SMILES / InChI

Molecular Formula C23H21N5O3S
Molecular Weight 447.51
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including http://www.4sc.de/wp-content/uploads/160621__4SC_CompanyPres_Citi.pdf

4SC-202 is an epigenetic oncology compound with a unique therapeutic profile, which was developed by biotechnology company: 4SC. 4SC-202 works as a selective inhibitor of LSD1 (lysine-specific demethylase 1) and HDAC (histone deacetylase) 1, 2 and 3. 4SC-202 also strengthens the endogenous immune response to cancer tissue. This compound demonstrated successfully completed Phase I of the clinical study, where it was proved safe and well tolerated in patients with advanced hematologic cancer. In addition, 4SC-202 shows substantial anti-tumor activity in a broad range of cancer cell lines including hepatocellular carcinoma, Urothelial Carcinoma Cell Lines and colorectal cancer.

Approval Year

T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
146 h
200 mg 2 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
4SC-202 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Pre-clinical characterization of 4SC-202, a novel class I HDAC inhibitor, against colorectal cancer cells.
2016 Aug
Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines.
2016 Dec
4SC-202 activates ASK1-dependent mitochondrial apoptosis pathway to inhibit hepatocellular carcinoma cells.
2016 Mar 4
Patents

Sample Use Guides

oral administration dose escalation twice daily (bid) or three times a day (tid) continuous dosing for 21 days per cycle
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: 4SC-202 treatment induced potent cytotoxic and proliferation-inhibitory activities against established hepatocellular carcinoma (HCC) cell lines (HepG2, HepB3, SMMC-7721) and patient-derived primary HCC cells. Further, adding 4SC-202 in HCC cells activated mitochondrial apoptosis pathway, which was evidenced by mitochondrial permeability transition pore (mPTP) opening, cytochrome C cytosol release and caspase-3/-9 activation. 4SC-202 induced apoptosis signal-regulating kinase 1 (ASK1) activation, causing it translocation to mitochondria and physical association with Cyp-D. This mitochondrial ASK1-Cyp-D complexation appeared required for mediating 4SC-202-induced apoptosis activation. ASK1 stable knockdown by targeted-shRNAs largely inhibited 4SC-202-induced mPTP opening, cytochrome C release, and following HCC cell apoptotic death.
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 23:35:08 GMT 2025
Edited
by admin
on Mon Mar 31 23:35:08 GMT 2025
Record UNII
264ARM7UXX
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
4SC-202
Preferred Name English
DOMATINOSTAT
INN  
Official Name English
2-PROPENAMIDE, N-(2-AMINOPHENYL)-3-(1-((4-(1-METHYL-1H-PYRAZOL-4-YL)PHENYL)SULFONYL)-1H-PYRROL-3-YL)-, (2E)-
Systematic Name English
domatinostat [INN]
Common Name English
(E)-N-(2-AMINOPHENYL)-3-(1-((4-(1-METHYL-1H-PYRAZOL-4-YL)PHENYL)SULFONYL)-1H-PYRROL-3-YL)ACRYLAMIDE
Systematic Name English
HDAC INHIBITOR 4SC-202
Common Name English
Domatinostat [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C129825
Created by admin on Mon Mar 31 23:35:08 GMT 2025 , Edited by admin on Mon Mar 31 23:35:08 GMT 2025
NCI_THESAURUS C1946
Created by admin on Mon Mar 31 23:35:08 GMT 2025 , Edited by admin on Mon Mar 31 23:35:08 GMT 2025
Code System Code Type Description
NCI_THESAURUS
C96797
Created by admin on Mon Mar 31 23:35:08 GMT 2025 , Edited by admin on Mon Mar 31 23:35:08 GMT 2025
PRIMARY
DRUG BANK
DB13101
Created by admin on Mon Mar 31 23:35:08 GMT 2025 , Edited by admin on Mon Mar 31 23:35:08 GMT 2025
PRIMARY
PUBCHEM
15985904
Created by admin on Mon Mar 31 23:35:08 GMT 2025 , Edited by admin on Mon Mar 31 23:35:08 GMT 2025
PRIMARY
SMS_ID
100000181106
Created by admin on Mon Mar 31 23:35:08 GMT 2025 , Edited by admin on Mon Mar 31 23:35:08 GMT 2025
PRIMARY
FDA UNII
264ARM7UXX
Created by admin on Mon Mar 31 23:35:08 GMT 2025 , Edited by admin on Mon Mar 31 23:35:08 GMT 2025
PRIMARY
INN
10700
Created by admin on Mon Mar 31 23:35:08 GMT 2025 , Edited by admin on Mon Mar 31 23:35:08 GMT 2025
PRIMARY
CAS
910462-43-0
Created by admin on Mon Mar 31 23:35:08 GMT 2025 , Edited by admin on Mon Mar 31 23:35:08 GMT 2025
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
4SC-202 is a selective class I HDAC inhibitor and also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.
INHIBITOR
IC50
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
4SC-202 is a selective class I HDAC inhibitor and also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.
INHIBITOR
IC50
TARGET -> INHIBITOR
4SC-202 is a selective class I HDAC inhibitor and also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.
INHIBITOR
IC50
Related Record Type Details
ACTIVE MOIETY